Key Highlights
- Shares are trading up 17.61% at $23.78, near the $23.93 52-week high.
- Third-quarter Revenue grew 14.5% to $55.7 million with a loss of $0.08 per share.
- Full-year revenue guidance of $231 million to $233 million was reaffirmed.
SI-BONE (NASDAQ:SIBN) shares are trading up 17.61% at $23.78 today after third-quarter results beat consensus and management reaffirmed 2026 revenue guidance. The stock is near its 52-week high of $23.93, against a 52-week low of $11.48, on Volume roughly four times average, reversing a 4.8% decline in the prior session.
SI-BONE is a Santa Clara, California-based medical device company founded in 2008 that pioneered minimally invasive sacroiliac joint fusion with its iFuse Implant System. Its portfolio includes iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite, 3D-printed titanium implants for sacroiliac joint dysfunction, adult spinal deformity and pelvic trauma, sold mainly through a direct U.S. sales force.
A Beat on Revenue and a Narrower Loss Than Expected
Worldwide revenue grew 14.5% to $55.7 million against estimates near $55.3 million, with U.S. revenue up 13.9% to $52.8 million on 19.5% procedure volume growth. Active physicians rose 16% to about 1,770, while average selling price was lower on procedure and site-of-care mix. International revenue rose 27% to $2.9 million.
Gross Margin was 79.3%, and adjusted EBITDA rose 32.4% to $3.0 million, a 5.5% margin. The net loss narrowed to $3.6 million, or $0.08 per share, against an expected $0.13 loss, and cash ended the quarter at $146.3 million. Operating Expense growth is now expected at 10.5%, down from 12%.
iFuse Granite Onyx and New DRGs Support the Fourth-Quarter Outlook
Guidance for worldwide 2026 revenue of $231 million to $233 million was reaffirmed, implying more than 20% growth in the fourth quarter, with gross margin expected at about 79%. Onyx received FDA 510(k) clearance in September and entered Alpha launch in October, with early Demand tracking ahead of Granite and only a modest fourth-quarter contribution expected. Full launch is planned for January, and the company sizes the U.S. market for Onyx at roughly $1.5 billion.
New Granite diagnosis-related group codes took effect on October 1 and could add up to $50,000 per qualifying case, and proposed CMS changes for sacroiliac joint fusion would include a $20,000 office payment from January 1, 2027 if finalized. An NTAP application has been submitted and, if approved, would take effect on October 1, 2027.
Analyst Targets Cluster Between $23 and $32
UBS raised its target to $26, TD Cowen sits at $23, Citizens reiterated $32 and Needham trimmed to $26. Some pricing pressure remains, with average selling price down about 5%. Management declined to give 2027 guidance until late February but expects modest gross margin pressure and long-term Operating Leverage of 1.25x to 1.75x.
January Onyx Launch and 2027 Guidance Are the Next Catalysts
With the stock at a 52-week high and healthcare sector gains muted, the move looks stock-specific. The full Onyx launch in January and 2027 guidance in late February are the next milestones for the rally.






Please wait processing your request...